Heritage Pharma Admits Price Fixing, Aids DOJ Probe

Law360 (May 31, 2019, 9:32 PM EDT) -- Heritage Pharmaceuticals has admitted conspiring to fix prices for a diabetes drug and has given prosecutors "substantial and ongoing cooperation" to assist a long-running criminal investigation involving other generic-drug makers, the U.S. Department of Justice said Friday.

Heritage made the admission as part of a deferred prosecution agreement involving a newly filed felony charge under the Sherman Act for fixing prices and allocating customers for the diabetes drug glyburide. The agreement was warranted because Heritage has disclosed information about "criminal antitrust violations" involving other drugs and drugmakers, the DOJ said.

"This cooperation has allowed the United States to advance its investigation...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!